The agency granted the accelerated approval for Datroway in EGFR-mutant NSCLC based on data from the TROPION-Lung05 and TROPION-Lung01 trials.

The funding comes from the Foundation Fighting Blindness' venture philanthropy arm, the Retinal Degeneration Fund.

Top-line results from a Phase III trial showed an overall survival benefit for zanzalintinib combo therapy in microsatellite-stable colorectal cancer.

Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

NEW YORK – OCCAM Immune, a research organization within Mount Sinai, announced a long-term partnership this week with the Cancer Research Institute to identify which cancer patients respond best to ...

The US subsidiary will focus on advancing PolTreg's pipeline, including its lead candidate PTG-007 in type 1 diabetes, in these new territories.

NEW YORK – SunRock Biopharma and Escugen on Tuesday said they've partnered to codevelop the antibody-drug conjugate (ADC) SRB123 as a treatment for solid tumors that overexpress CCR9. Escugen, ...

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

Lyell Immunopharma announced new clinical data Tuesday from a Phase I/II trial of its dual-targeted CD19/CD20 CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. The company ...